ALX Oncology

Contributing Author

Recent Articles by ALX Oncology

Sep-28	ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer ALXO +6.11% GlobeNewswire
Sep-02	ALX Oncology to Present at Upcoming Investor Conferences in September ALXO +5.05% GlobeNewswire
Aug-06	ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update ALXO +9.90% GlobeNewswire
Jun-30	ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules ALXO -5.91% GlobeNewswire
Jun-30	ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel ALXO -5.91% GlobeNewswire
Jun-01	ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York ALXO -5.26% GlobeNewswire
May-08	ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update ALXO +11.23% GlobeNewswire
May-07	ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression ALXO -10.53% GlobeNewswire
Apr-30	ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 ALXO +7.59% GlobeNewswire
Apr-17	ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules ALXO GlobeNewswire
Apr-13	ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer ALXO GlobeNewswire
Feb-27	ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update ALXO -10.21% GlobeNewswire
Feb-19	ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 ALXO +12.07% GlobeNewswire
Feb-19	ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 ALXO +12.07% GlobeNewswire
Jan-30	ALX Oncology Announces Pricing of Underwritten Offering ALXO +10.83% GlobeNewswire
Jan-30	New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer ALXO +10.83% GlobeNewswire
Jan-08	ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference ALXO +5.08% ALXO +8.87% GlobeNewswire
Jan-08	ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 ALXO +5.08% GlobeNewswire
Dec-07	ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting ALXO GlobeNewswire
Nov-18	ALX Oncology to Present at Upcoming Investor Conferences ALXO ALXO -9.82% GlobeNewswire
Nov-07	ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update ALXO +16.95% GlobeNewswire
Oct-30	ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting ALXO GlobeNewswire
Oct-23	ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference ALXO +8.70% GlobeNewswire
Oct-03	ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting ALXO +14.14% GlobeNewswire
Sep-12	ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer ALXO -10.17% GlobeNewswire
Aug-29	ALX Oncology to Participate in Upcoming Investor Conferences in September ALXO ALXO -11.97% GlobeNewswire
Aug-19	ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors ALXO -8.37% GlobeNewswire
Aug-12	ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update ALXO ALXO +7.40% GlobeNewswire
Aug-05	ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 ALXO +12.68% GlobeNewswire
May-30	ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference ALXO GlobeNewswire
May-20	ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event ALXO GlobeNewswire
May-13	ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 ALXO +10.52% GlobeNewswire
May-08	ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update ALXO GlobeNewswire
May-02	ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 ALXO GlobeNewswire

ALX Oncology

Recent Articles by ALX Oncology

Upgrade your Finviz experience